Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation
Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation
复制标题
DOI：
10.1111/j.1464-410x.2006.06398.x
复制
发表时间：
2006-11-01
影响因子：
4.5
通讯作者：
Stock, Richard G.
中科院分区：
文献类型：
--
作者：
Lehrer, Steven;Cesaretti, Jamie;Stock, Richard G.
目的探讨前列腺癌近距离放射治疗前性功能和下尿路症状(LUTS)的关系。方法1991年6月至2002年9月，854例前列腺癌患者接受经直肠B超引导下会I-125前列腺间质内放射治疗。使用国际前列腺症状评分(IPSS)，在治疗前和每隔一段时间自我给药并前瞻性收集有关排尿功能的详细信息。使用男性性健康问卷(Shim)评估性功能，这是一种由五个问题组成的自我诊断测试，可以帮助指示勃起功能障碍(ED)的存在或不存在。我们使用以前建立的标准来评估前列腺特异性抗原(PSA)失败的风险，方法是将男性分为三个风险组，即低风险组，PSA水平为
OBJECTIVE To examine the relationship of 'symptom flare' with sexual function and lower urinary tract symptoms (LUTS) before brachytherapy, as we noted that after brachytherapy for prostate cancer, some patients had recurrent LUTS after an asymptomatic period; this secondary exacerbation of symptoms ('symptom flare') occurred at approximate to 2 years after implantation and was transient in most patients.PATIENTS AND METHODS In all, 854 patients with organ-confined prostate carcinoma had transrectal ultrasonography-guided transperineal I-125 interstitial brachytherapy of the prostate gland between June 1991 and September 2002, and were considered candidates for this study. Detailed information on urinary function was self-administered and prospectively collected before treatment and at intervals using the International Prostate Symptom Score (IPSS). Sexual function was evaluated with the Sexual Health Inventory for Men (SHIM), a five-question, self-administered diagnostic test that can help to indicate the presence or absence of erectile dysfunction (ED). We used previously established criteria to estimate the risk of prostate-specific antigen (PSA) failure by dividing the men into three risk groups, i.e. low-risk, with a PSA level of